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One of the most striking features of the Xenopus system is the versatility in providing a unique range of
both in vitro and in vivo models that are rapid, accessible and easily manipulated. Here we present an
overview of the diverse contribution that Xenopus has made to advance our understanding of tumour
biology and behaviour; a contribution that goes beyond the traditional view of Xenopus as a deve-
lopmental model organism. From the utility of the egg and oocyte extract system to the use of whole
embryos as developmental or induced tumour models, the Xenopus system has been fundamental to
investigation of cell cycle mechanisms, cell metabolism, cell signalling and cell behaviour, and has
allowed an increasing appreciation of the parallels between early development and the pathogenesis of
tumour progression and metastasis. Although not the prototypical oncological model system, we
propose that Xenopus is an adaptable and multifunctional tool in the oncologist's arsenal.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction: the versatile Xenopus system applied to oncology
Since the 1950s, Xenopus laevis has become the most widely used
amphibian research organism (Schmitt et al., 2014), with unique
versatility in providing a range of both in vitro and in vivo models
that are rapid, accessible and easily manipulated. The collective use
of Xenopus oocytes, egg extracts, cell cultures and whole embryos in
cancer research has made valuable contributions to understanding
tumour biology, as well as improving therapeutic options in both
diagnostics and chemotherapeutics.
Modelling with Xenopus eggs and cleavage stage embryos
Investigating cell cycle mechanisms
The events and regulatory mechanisms governing the cell cycle
are essential for regulation of cellular proliferation and genomic
stability, and several checkpoints exist to ensure successful comple-
tion of one stage before progression to the next (Harper and Brooks,
2005). Not only are pathways involved in cell cycle control frequently
mutated in cancer, but deregulation of the cell cycle checkpoints
promotes further acquisition of DNA mutations that can progress a
cell down the route to metastasis (Laiho and Latonen, 2003).
Xenopus oocytes, eggs and early embryos have served as funda-
mental experimental systems inwhich to elucidate the mechanisms of
the cell cycle and the coordination of the cell cycle and differentiation
during development (e.g. Ali et al., 2011; Felix et al., 1990; Felix et al.,
1989; Minshull et al., 1990; for a review, see Philpott and Yew, 2008).
Large volumes of extracts can be prepared from eggs and oocytes by
centrifugation, and these contain vast arrays of proteins that enable
reconstitution of cell cycle events, nuclear transportation, microtubule
polymerisation and apoptosis (e.g. Blow and Laskey,1986; Laskey et al.,
1978; Leno et al., 1992; Nutt, 2012; Zylkiewicz and Stukenberg, 2014;
Deming and Kornbluth, 2006). Moreover, the cell-free nature of the
extract system means the molecular machinery involved in these
processes can be probed by manipulation of extracts with immune-
depletion or neutralisation of an endogenous protein of interest,
followed by subsequent rescue by addition of recombinant protein
(e.g. Srinivasan and Gautier, 2011; Yew and Kirschner, 1997). Similar
approaches allow the identiﬁcation of endogenous targets of drug
compounds that inﬂuence cell cycle kinetics (Rosania et al., 1999).
Extracts can also be prepared to represent different phases of the cell
cycle, and these, for example, can be used to study changes in protein
stability during the cell cycle (McDowell et al., 2014; Vosper et al.,
2009).
Given this impressive versatility, it is not surprising that the
Xenopus egg extract system can also be applied to study the
molecular derangements of cell cycle events that promote or
accompany neoplastic transformation. In particular, biochemical
investigation of the control of DNA replication, of DNA repair and
of checkpoint control has been extensive. Plasmid replication can
be studied in “nucleus-free” systems, but classic DNA replication
experiments involve the addition of demembranated sperm chro-
matin to unfertilised egg extracts, which results in the formation
of nuclei that undergo semi-conservative, cell-cycle regulated DNA
replication (Leno and Laskey, 1991; Srinivasan and Gautier, 2011).
Using this system, work has characterised the biochemical aspects
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of control of the replication process (Blow, 2001; Dikovskaya et al.,
2012) and DNA replication fork stability (Hashimoto and Costanzo,
2011). Addition of linear DNA fragments to Xenopus egg extracts
mimics the effects of double strand breaks in genomic DNA,
enabling study of DNA damage checkpoints in a cell-free model
(Willis et al., 2012; You et al., 2007). Detailed methods are also
described for studying mitotic spindle assembly and checkpoints
(Desai et al., 1999), and many mitotic spindle factors that are
altered in cancer are conserved in Xenopus (Cross and Powers,
2009; Joukov et al., 2006).
However, Xenopus is not limited to in vitro investigation of
cell cycle function; the developing Xenopus embryo also presents
an interesting in vivo system to study regulation of proliferation
(Woodland, 1974) particularly in view of the changes in the cell cycle
regulation during early development (Saka and Smith, 2001). The
ﬁrst 12 embryonic cell cycles occur rapidly and synchronously,
driven by stockpiles of maternal proteins, and alternating between
DNA replication in S phase and cell division in M phase (Philpott and
Yew, 2008). The mid-blastula transition (MBT) marks the onset of
zygotic transcription, after which cell cycles become asynchronous
and gradually lengthen with incorporation of G1 and G2 phases
(Newport and Kirschner, 1982a, b). Furthermore, the cell cycle is
intimately linked with the process of differentiation during devel-
opment (for example Carruthers et al., 2003; Vernon et al., 2006)
and for review see (Hardwick and Philpott, 2014). As well as
providing a platform for studying in vivo mechanisms of cell cycle
control, the ease of experimental manipulation lends itself to
investigate the mechanistic links between proliferation and differ-
entiation, links that are often perturbed in cancer (Vernon et al.,
2003; Richard-Parpaillon et al., 2004; Ali et al., 2011; Hindley et al.,
2012).
Using Xenopus oocytes to model cancer cell signalling
Distinct from studying somatic cell division, the Xenopus oocyte
has also proven to be a highly versatile and powerful tool for
investigating signalling cascades and their effects on cell growth.
The large size of the oocyte enables microinjection of substances
without disturbance of the normal physiology (Woodland, 1974) and
components of signalling paths can be studied in isolation from the
complex milieu of growth signals that complicate the endogenous
tumour environment (Cailliau et al., 2005; Browaeys-Poly et al.,
2009). For example, tumour-secreted ﬁbroblast growth factor 1
(FGF1) and tumour-expression of its receptor FGFR1 are involved in
the proliferation of oestrogen-negative human breast cancer cells
(Cailliau et al., 2005). Xenopus oocytes lack endogenous FGFRs,
enabling the study of FGFR1 receptors derived from malignant breast
cancer cell lines following oocyte over-expression. Stimulation of the
exogenous receptors by in vitro applied FGF ligands triggers oocyte
maturation and passage through the G2/M transition that serves as a
read-out of FGF signal transduction (Cailliau et al., 2005). This model
has been used to characterise the downstream components respon-
sible for this transition into M phase (Browaeys-Poly et al., 2009), and
also to identify potential pharmacological inhibitors of this pathway
(Cailliau et al., 2005).
Xenopus oocytes and cancer metabolism
The Xenopus oocyte has also found favour in the studies of cancer
metabolism. In this respect, the oocyte has the advantage of being
large enough to enable biochemical measurements in a single cell,
and allow microinjection of compounds that would otherwise
require the use of harsh permeabilisation techniques in heterogenous
populations of cells (Ureta et al., 2001). Indeed, the Xenopus oocyte
has been described as a “living test-tube” inwhich to studymetabolic
regulation (Ureta et al., 2001). It is perhaps not surprising therefore,
that the oocyte has also formed an in vitro model for the study of
deranged metabolism in cancer cells. A detailed discussion is beyond
the scope of this review, but interestingly, the metabolic phenotypes
and intermediary pathways seen in cancer cells are similar to those
found in the Xenopus oocyte, enabling the extract system to model
the relationship between cancer metabolism and cell death (Deming
and Kornbluth, 2006; Dworkin and Dworkin-Rastl, 1989) and for
review see (Nutt, 2012). Furthermore, over-expression of tumour-
associated signalling proteins and nutrient transporters in Xenopus
oocytes can serve as a model to study alterations in glucose handling
by tumour cells, (for example Pakladok et al., 2012). Overall, these
Xenopus assays have already contributed to cancer metabolomics but
also provide viable models for future investigations into therapeutic
targeting of abnormal cancer metabolism.
Xenopus embryogenesis: a developmental model for cancer
studies
Parallels between early development and tumourigenesis
From as early as the 1890s, parallels were drawn between the
development of the early embryo and the pathological develop-
ment of neoplasia. Over a century of research has built on these
foundations and a body of literature now documents the simila-
rities in terms of epigenetic signatures, transcriptomes, proteomes,
metabolism and cell behaviour (Ma et al., 2010; Wang, 2009;
Wu et al., 2007; Xie and Abbruzzese, 2003). Signalling pathways
that are critical during embryonic development (such as Sonic
Hedgehog, Wnt, Notch and Bone Morphogenetic Proteins) are also
instrumental in tumour progression to a metastatic phenotype
(Bailey et al., 2007). Similarly, high rates of cell proliferation are
seen in both embryonic and tumour cells, in part due to the
activity of pro-proliferative signalling pathways and transcription
factors (Ma et al., 2010). Therefore cancer can perhaps be viewed
as an inappropriate re-activation or alteration of normal embryo-
nic growth pathways (Pennisi, 1998), or perhaps a disorder of
cellular differentiation, where cells instead remain locked in the
proliferative mode prior to cell fate determination, as seen in some
induced tumour models (Wallingford et al., 1997). In this respect,
characterisation of normal developmental pathways can assist in
understanding the derangements that occur during oncogenesis,
and also aid in the identiﬁcation of potential novel diagnostic or
therapeutic targets. Acknowledged beneﬁts of the Xenopus system
include the accessibility of the early developmental stages and the
ease of targeted expression due to accurate fate maps. These
enable Xenopus to form an instrumental model for developmental
biologists and oncologists alike (Wallingford, 1999).
Characterising oncogenes: induced tumours in developing Xenopus
embryos
In the late 1990s, three independent groups reported induced
tumour phenotypes in developing Xenopus embryos. This was achieved
either through over-expression of oncogenes such as Gli1 (Dahmane
et al., 1997) or Xrel3 (Yang et al., 1998), or through inhibition of tumour
suppressor protein p53 (Wallingford et al., 1997). Histologically these
induced tumours contain poorly differentiated cells with abnormal
nuclear morphologies (Wallingford, 1999), and in the case of Gli1-
induced epidermal growths, the molecular phenotype suggests that
these tadpole tumours may be equivalent of human basal cell
carcinomas (Dahmane et al., 1997). Subsequent work has referred to
these lesions as induced tumour-like structures (ITLS), characterised by
disorganised undifferentiated cells with increased proliferation and
abnormal nuclear size, invasive behaviour and the ability to stimulate
angiogenesis (Chernet and Levin, 2014). Thus, from this early work,
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Xenopus has gained increasing credibility as a valid in vivo model for
various forms of human malignancy, in addition to the potential for
functional screening for therapeutic agents that may diminish the
induced tumour phenotype (Wallingford, 1999).
Interestingly, the early work that uncovered a tumourigenic
phenotype from inhibition of p53 in Xenopus embryos, was originally
undertaken to characterise the role of p53 during early embryogen-
esis. Xenopus was used as a rapid developmental model to minimise
the effects of genetic instability resulting from p53 knockdown
(Wallingford et al., 1997). Tumour cells divide normally, but fail to
undergo the normal differentiation process (Wallingford et al., 1997),
and this may therefore support the view that cancer is sometimes a
failure of differentiation rather than abnormal proliferation per se.
Similarly, the dose-dependent tumourigenic phenotype from over-
expression of Xrel3 was realised following identiﬁcation of this novel
c-rel homologue during early development; the authors suggest that
the endogenous Xrel3 function may be in the cellular proliferation
versus differentiation decision (Yang et al., 1998).
These examples highlight the importance of examining the
parallels between development and tumourigenesis, not only to
uncover cellular functions for known oncogenes, but also to assist
identiﬁcation of potential oncogenic activity in genes with a
known developmental function. In this way, viral and cellular
proto-oncogenes have been found to have endogenous develop-
mental roles, for example as p21ras (Whitman and Melton, 1992).
Conversely, human homologues of developmental regulators have
been identiﬁed as having key oncogenic or tumour suppressor
roles. For example, the presence of anterior gradient 2 (AGR2), a
human homologue of the Xenopus cement-gland speciﬁc gene,
correlates with and can even confer metastatic phenotype in
human breast carcinomas (Liu et al., 2005), whereas VentX, the
human homologue of Xenopus homeobox transcription factor
Xom, induces senescence in osteosarcoma and lymphoblastic
leukaemia cell lines (Wu et al., 2011).
Developing Xenopus embryos can also be used to probe the
molecular mechanisms of oncogenes in signalling pathways. For
example, HGF/SF (hepatocyte growth factor scatter factor) is a ligand
for activation of the Met tyrosine kinase receptor, and aberrant
activity of this pathway contributes to tumour cell invasion and
metastasis in a number of human cancers (Ishimura et al., 2006).
Over-expression of oncogenic mutant forms of Met receptor in
Xenopus embryos leads to the formation of ectopic morphogenic
structures, thereby providing a rapid in vivo assay of tumorigenesis.
This model has enabled identiﬁcation of downstream components
that contribute to the oncogenic deregulation of this pathway
(Ishimura et al., 2006).
In recent years, several powerful genome editing techniques
have become available for use in Xenopus, opening the way to
advanced genetic modiﬁcations that are already established in
murine models; these include the use of zinc-ﬁnger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs) and
CRISPR/Cas system, as reviewed in (Schmitt et al., 2014). Combined
with the expanding number of transgenic frog lines, it will surely
not be long before transgenic models are generated to model
various aspects of speciﬁc mammalian cancers. Such a technique
has recently been employed to produce a transgenic Xenopus
model to study lymphangiogenesis (Ny et al., 2005; Ny et al.,
2013). With an increasingly appreciation of the underlying genetic
derangements in speciﬁc types of human cancers, this will be an
interesting avenue to pursue with Xenopus transgenics.
Wnt signalling in development and cancer
The Wnt signalling pathway has vital roles at different stages in
embryonic development, regulating processes including cell pro-
liferation and cell fate speciﬁcation, cell migration and polarity,
and body axis formation (Hikasa and Sokol, 2013). Yet aberrant
activity of Wnt ligands and their downstream effectors are also
important for tumour initiation, growth, progression and metas-
tasis, with acknowledged roles in breast, prostate, gastro-intest-
inal, liver and lung cancers, in addition to melanoma and bone
metastasis (Xi and Chen, 2014; Tumova et al., 2014).
Different intracellular signalling cascades can be activated down-
stream of the active Wnt-Frizzled receptor, in part due to the
diversity of Wnt ligand families that primarily activate one or more
pathways and have conﬂicting effects on cell behaviour (Gradl et al.,
1999). Canonical Wnt signalling refers to activation of the Wnt/β-
catenin pathway by Wnt-1 family ligands. Non-canonical Wnt
pathways include activation of the Wnt/Ca2þ pathway and the
Wnt/planar cell polarity (PCP) pathway, usually by Wnt-5A family
members (Kuhl, 2002). These signalling cascades are highly con-
served in evolution, and Xenopus has provided rapid assay methods
to investigate various aspects of pathway regulation. The most well-
established assay for canonical Wnt signalling is the Xenopus axis
duplication assay (Fig. 1), but Xenopus oocytes can also be used as a
secretory system to release human Wnt ligands for a variety of
paracrine assays (Cha and Heasman, 2010), and CaMKII activity in
Xenopus embryos can provide a measure of non-canonical Wnt
signalling (Kuhl and Pandur, 2008b).
Given the instrumental role that aberrant Wnt signalling can
have in cancer progression, inhibition of this pathway has proved to
be an attractive chemotherapeutic target, and the Xenopus axis
duplication assay is a highly efﬁcient screen for potential candidate
inhibitors (see below and Kuhl and Pandur, 2008a). Endogenously,
β-catenin is stabilised on the prospective dorsal side of the embryo
during the ﬁrst cell cycle, due to the cortical rotation that follows
sperm entry. This leads to activation of transforming growth factor-β
(TGFβ) family members siamois and Xenopus nodal-related 3 (Xnr-3),
that promote formation of dorsal structures. Injection of mRNA
RNA encoding βcatenin injected into 
a ventral cell at the 4 cell stage
Normal neurula stage 
embryo stained for 
neural-β-tubulin
Neurula stage embryo with 
duplicated axis, stained for 
neural-β-tubulin
Fig. 1. (A) A secondary axis can be induced in developing Xenopus embryos by
injection of RNA encoding β-catenin into a ventral cell of 4-cell stage embryos.
Ventral cells are usually distinguished by their larger size and darker pigment
compared to dorsal cells. For detailed methods see (Kuhl and Pandur, 2008a).
(B) The duplicated axis is visible in neurula stage embryos within 2 days of
injection. Embryos in these images have undergone in situ hybridisation for neural-
β-tubulin to illustrate the bilateral stripes of primary neurons and trigeminal
ganglia. Embryos can be exposed to a range of compounds during development to
assay for ability of the compound to inhibit axis duplication. Alternatively, RNA
encoding proteins of interest can be injected into the ventral cells to assay for
ability of the protein to induce a secondary axis.
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encodingWnt ligand or β-catenin into the marginal zone of a ventral
blastomere of a 4-cell stage Xenopus embryo results in duplication of
the body axis, with results visible from neurula stages, just 36 h after
injection (Kuhl and Pandur, 2008a).
Epithelial to mesenchymal transitions in development and cancer
One of the most striking examples of the similarity between
embryonic development andmalignant behaviour is presented by the
morphological changes that accompany epithelial to mesenchymal
transitions (EMT) in development and cancer. These EMT and
mesenchymal to epithelial (MET) events are fundamental changes
of cell shape, polarity and migration that are central but transient
events during embryogenesis, and are responsible for processes such
as blastula formation, gastrulation, neural crest formation, somitogen-
esis and cardiac morphogenesis; for detailed reviews see (Acloque
et al., 2009; Acloque et al., 2008; Kalluri and Weinberg, 2009; Nakaya
and Sheng, 2013; Theveneau and Mayor, 2012; Thiery et al., 2009).
These transitions may be complete or partial during embryogenesis,
but nevertheless they provide essential insights into behaviours that
can be inappropriately reactivated during tumour progression, while
EMT is a key event in malignant invasion (Vernon and la Bonne,
2004). Indeed, genes that have pivotal roles in EMT events during
embryogenesis are often mutated or aberrantly expressed in cancer
cells (Lander et al., 2013; Mani et al., 2007; Nakaya and Sheng, 2013;
Taube et al., 2010; Vernon and LaBonne, 2004; Yang et al., 2004); this
underscores the importance of understanding the developmental
regulation of this process.
In this way, study of embryonic neural crest cells is often used
as an in vivo and in vitro model of EMT, with neural crest cells
displaying the activity of signalling paths, transcription factors,
cell-adhesion changes and matrix remodelling that are similarly
responsible for invasion and metastasis of epithelial tumours,
comprehensively reviewed in (Theveneau and Mayor, 2012). This
developmental approach has highlighted the importance of the
bHLH protein Twist, for both embryonic and cancer-associated
EMT (Vernon and LaBonne, 2004; Yang et al., 2004), with Xenopus
neural crest formation serving as a model to investigate the role
and regulation of Twist (Lander et al., 2013). Twist is similarly
considered a master regulator of EMT in malignant breast cancer,
highly expressed in tumour cells yet rarely expressed in normal
adult cells, therefore generating interest as a potential therapeutic
target (Glackin, 2014). Additionally, the study of epithelial cell
behaviour can also be conducted using the established Xenopus A6
cell line. These cells are derived from normal Xenopus kidney
tissue, and behave in vitro as typical polarised epithelial mono-
layers, and therefore are suitable for investigating epithelial cell
migration and morphogenesis (Mimori-Kiyosue et al., 2007).
Taken together, these examples highlight the complementary
ﬁelds of developmental biology and oncology, and how advances in
one area can prove directly relevant to understanding the molecular
mechanisms in the other. Signalling pathways and morphogenic
events in development are highly conserved between species;
Xenopus is therefore a highly pertinent model for elucidating these
critical components.
Spontaneous tumours and tumour resistance in Xenopus
Spontaneous tumours in amphibians are rare (Ruben et al., 2007),
but even this phenomenon can nevertheless make a valuable contri-
bution to mammalian cancer biology. The multi-step process through
which a cell progresses in order to gain a fully malignant phenotype
has been well characterised in mammals, both at cellular and genetic
levels (Hanahan and Weinberg, 2000, 2011). What are less well
characterised are the complex and multiple interactions that exist
between tumour cells and the host immune system. In one respect,
“cancer immune-surveillance” describes the detection and destruc-
tion of tumour cells by the host immune system. Conversely, the
immune system can exert a selection pressure on the heterogenous
tumour cell population, leading to the persistence and growth of
resistant or less immunogenic cells in the process of “immune-
editing” (Bui and Schreiber, 2007). Xenopus has played a key role in
both in vitro and in vivo studies of anti-tumour immune responses,
providing evidence for both of these mechanisms (Goyos and Robert,
2009).
Spontaneous tumours
Despite the relatively lower incidence of spontaneous tumours in
Xenopus compared to mammalian models, several neoplastic con-
ditions have been described, including hepatomas (Robert, 2010),
ovarian tumours (Goyos and Robert, 2009), and thyroid-containing
teratomas (Cheong et al., 2000). The deﬁnition of neoplasia in
Xenopus has come under some scrutiny, as the original report of a
virally-induced and highly malignant lymphosarcoma (Balls, 1965)
was subsequently shown to be a transmissible (but not transplan-
table) infectious granuloma (Asfari and Thiebaud, 1988), caused by
myocobacterium marinum (Asfari, 1988). However, the most experi-
mentally useful tumours have proven to be the thymic lymphomas,
ﬁrst recorded in the early 1990s and subsequently described in
4 genetically different adult Xenopus frogs at the Basel Institute of
Immunology (du Pasquier and Robert, 1992; Robert et al., 1994), and
one at the Tulane University Xenopus colony (Earley et al., 1995). The
tumours fulﬁl the criteria for spontaneous neoplasia, propagating in
isogenic animals, being rejected in allogenic animals and enabling
the derivation of stable lymphoid cell lines that can be cloned from
single cells and cultured indeﬁnitely (du Pasquier and Robert, 1992).
Characteristics of the 5 lymphoid cell lines (B3B7, 15/40, 15/0, ff-2
and ff2.64) are comprehensively reviewed elsewhere (Robert and
Cohen, 1998), and while all are mixed T/B cell phenotypes, they
appear to arise from independent oncogenic events (Robert et al.,
1994). These cell lines also demonstrate aneuploidy with marked
genetic instability in addition to up-regulation of c-myc (Goyos and
Robert, 2009), thus illustrating their relevance as in vitro and in vivo
models of mammalian cancer biology.
Tumour resistance in amphibians
The relative resistance of Xenopus (and other amphibians) to
spontaneous and transplanted tumours has provided an intriguing
model to study the mechanisms of tumour immunity. A range of
developmental and physiological features in amphibians may
contribute to their relative tumour resistance, as reviewed in
(Ruben et al., 2007), and metamorphosis provides a particularly
interesting evolutionary perspective with respect to differences
between the more primitive larval immune system and that found
in the adult (Robert and Cohen, 1998). The stable lymphoid cell
lines derived from the different thymic tumours have been used in
transplantation studies to determine components of the laval or
adult immune system that are required to afford tumour immunity
(du Pasquier and Robert, 1992; Robert et al., 1997). Together, these
studies have demonstrated a conserved and critical function of T
cells in tumour immunity, directed against tumour-speciﬁc anti-
gens (Robert et al., 1997). Furthermore, recent work has identiﬁed
molecular mechanisms involving expression of class Ib MHC
molecules that may be responsible for immune evasion by the
15/0 tumour cells (Haynes-Gilmore et al., 2014). In combination,
these studies support both the immune-surveillance and immune-
editing hypotheses, and it will now be interesting to translate
these ﬁndings to comparable mammalian tumour models.
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Xenopus contributions to translational medicine: insights that
may improve clinical approaches to cancer
From the discussion above, the Xenopus system has clear
relevance to our understanding of cancer aetiology, biology and
physiology, and from these studies, future therapeutic targets may
be identiﬁed. This ﬁnal section focuses more speciﬁcally on the
application of the Xenopus system to clinical practice, largely in the
form of developing chemotherapeutic agents, but we ﬁnish with a
novel and exciting avenue of Xenopus research into epigenetic
reprogramming of cancer cells.
Chemotherapeutic drug discovery
The contributions of the Xenopus system to drug discovery and
development again emphasises the versatility of this system, with
oocytes, isolated embryonic cells and whole embryo models avail-
able to researchers. Xenopus oocytes have served as a fundamental
tool in pharmaceutical research, from preliminary drug candidate
screening (Kvist et al., 2011; Landais et al., 2009) through to
characterisation of drug pharmacodynamics (Wei et al., 2013) and
drug pharmacokinetics and tumour targeting (Anderson et al., 2010).
This model has been used extensively to study the electrophysiology
of exogenous ion channels, and the activity of compounds to
modulate channel function in the search for new chemotherapeu-
tics, for example (Kvist et al., 2011). Injection of in vitro transcribed
cRNAs into oocytes can produce functional channel expression
within 2 days, and the large size of the oocyte is readily amendable
to patch clamp experiments or 2 electrode voltage clamping (Liu
et al., 2002; Pakladok et al., 2014). This approach can also aid
advances in diagnostic imaging, for example in characterising the
kinetics of radiotracers used in PET (positron emission tomography)
scans for visualising prostate cancer (Okudaira et al., 2013).
Secondly, isolated embryonic cells provide a rapid and efﬁcient
model for assaying the anti-proliferative effects of potential che-
motherapeutics (Miyata et al., 2004), and the utility of the whole
embryo axis duplication assay was mentioned earlier as a vital screen
for compounds affecting the canonical Wnt signalling path (Kuhl and
Pandur, 2008a). These studies have led to identiﬁcation of candidate
drugs that may assist in the future treatment of several human
cancers, particularly colon cancer (Tumova et al., 2014; Waaler et al.,
2012; Waaler et al., 2011) and glioblastoma (de Robertis et al., 2013).
Additionally, older tadpole stage embryos can also provide an assay
method to easily assess the effects of compounds on organ develop-
ment; progressive transparency acquired during tadpole stages ena-
bles direct visualisation of a range of organs and tissues. This has been
utilised to identify chemicals that suppress pigment cell development
with potential use in treatment of melanoma, and compounds with
anti-angiogenic or anti-lymphangiogenic activity that may have rele-
vance to inhibit tumour pathogenesis (Schmitt et al., 2014).
Xenopus extracts and epigenetic reprogramming
Another interesting recent ﬁeld of study has involved the possi-
bility of reprogramming cancer cells in order to reverse the epige-
netic changes that have resulted in gene activation or silencing at
certain critical gene promoters. From the pioneering nuclear transfer
experiments of John Gurdon and colleagues (Gurdon et al., 1958), the
ﬁeld of cellular reprogramming has advanced, with hopes of applica-
tion to disease modelling and ethically acceptable forms of regen-
erative medicine. Indeed, several techniques are now recognised for
directly or indirectly converting one somatic cell type to another, but
a caveat remains regarding aberrant reprogramming that can be
tumorigenic (Goding et al., 2014). Signiﬁcant investment is being
made to deﬁne cocktails of mammalian transcription factors that can
direct lineage conversion on over-expression (Lujan and Wernig,
2012; Ali et al., 2014), but Xenopus also presents experimental
systems for reprogramming by nuclear transfer (Halley-Stott et al.,
2013).
In addition to the established genetic mutations that have been
characterised in various human cancers, abnormal epigenetic altera-
tions have been ascribed roles in the pathogenesis of several different
human malignancies (Sadikovic et al., 2008). Epigenetics refers to
stable and heritable patterns of gene expression that contribute to
cellular phenotype, caused by mechanisms other than changes in
primary DNA nucleotide sequences (Halley-Stott and Gurdon, 2013).
However, epigenetic chromatin modiﬁcations are reversible and
therefore attractive targets to counteract malignancy (Allegrucci
et al., 2011). Extracts prepared from ovarian prophase axolotl oocytes
have previously been shown to remodel somatic mammalian cell
chromatin (Bian et al., 2009), and this work has since been extended
to demonstrate reprogramming of breast cancer cell lines by axolotl
and Xenopus oocyte extracts. Mechanistically, reactivation of silenced
tumour suppressor genes is achieved through promoter demethyla-
tion and histone remodelling, and phenotypically this is associated
with long term suppression of breast cancer cell tumourigenicity
(Allegrucci et al., 2011). Furthermore, this phenomenon has similarly
been demonstrated using bovine oocyte extracts to reprogram
human lung cancer cells, reactivating silenced tumour suppressor
genes without up-regulation of pluripotency-associated genes (Wang
et al., 2013a; Wang et al., 2013b)
The application of this technology to cancer studies will be
more as a method to study the epigenetic contribution to tumor-
igenesis, rather than a treatment per se. But future work may
uncover mechanisms that can be therapeutically targeted to
achieve a reversal of the epigenetic alteration, thus ameliorating
the malignant phenotype.
Concluding remarks: Xenopus as a complimentary system to
mouse and human cancer models
The preceding discussion has revealed the large contribution
that Xenopus has, and continues to make to mammalian oncology.
From an understanding of the basics of cell division and differ-
entiation, through oncogene function and cancer aetiology, to
characterisation of the molecular pathogenesis and metabolic
derangements of cancer, these insights from Xenopus may ulti-
mately translate into therapeutic beneﬁts in the form of new
prospective diagnostic tests or chemotherapeutics. Although not
the prototypical oncological model system, we propose that
Xenopus is an adaptable and multifunctional tool in the oncolo-
gist's arsenal; a tool that compliments the more extensively used
rodent models in cancer research.
Traditional approaches in rodent models have involved direct
genetic manipulations, often resulting in the generation of mice har-
bouring oncogenic mutations or missing tumour suppressor genes or
both (for instance Berry et al., 2012; Hingorani et al., 2005 but the list
is endless). Alternatively, and sometimes complimentarily, tumours
have been generated by chemical induction or through xenografted
tumourigenic tissues, often from patient cancers (for review, see
Cekanova and Rathore, 2014). These approaches have contributed to
both the study of oncogenic mechanisms and also to provision of pre-
clinical data prior to human trials.
Some advantages of these mammalian systems are obvious in
terms of recapitulating the accumulation of multiple genetic muta-
tions, complex tumour and stroma microenvironments, and
immune regulation that are seen in human patients. However,
mammalian models are not without their limitations in mimicking
human disease, and indeed, the complexity of rodent models can
itself hinder phenotypic analysis. For instance, cyclin-dependent
kinases (cdks) play a central role in cell cycle progression, yet
L.J.A. Hardwick, A. Philpott / Developmental Biology 408 (2015) 180–187184
knock-out mouse models of even key cdks such as cdk2 and cdk4
result in a remarkably mild phenotype (Berthet et al., 2003; Ortega
et al., 2003; Rane et al., 1999; Tsutsui et al., 1999). These highly
unexpected ﬁndings have been shown to result from redundancy
and/or facultative compensation between cdks (Santamaria and
Ortega, 2006). Reduced complexity is one reason why Xenopus can
triumph over rodents in such studies; for example, at early devel-
opmental stages studied, Xenopus has a single cdk inhibitor, p27Xic1,
which has characteristics of all 3 mammalian Cip/Kip family cdkis
(Vernon, 2003; Vernon and Philpott, 2003).
In cell division, differentiation and cancer, as in other areas, it is
remarkable how almost all of what we see in Xenopus is recapi-
tulated in mammalian cells and indeed in vivo in mice. This, once
again, underscores the high degree of conservation of fundamental
mechanisms amongst vertebrates, and it is clear that experiments
in Xenopus can usually be undertaken on vastly shorter time-scales
and at considerably smaller expense than those using mouse
models. These facts, coupled with the animal welfare and ethical
advantages of using eggs and tadpoles to replace rodents, means
that Xenopus remains a vital and if somewhat underused weapon
to provide initial observations that can then be extended into
mammalian models of cancer. If scientists using Xenopus and
mammalian models work together with a fuller understanding
of the merits and drawbacks of both systems, our combined efforts
will allow the maximum progress in the ﬁght against cancer.
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